The amyloid hypothesis is dead.

[anonymous]

Another knock back for amyloid: Roche's approach to presymptomatic Alzheimer's ends in failure | Fierce Biotech


https://www.fiercebiotech.com/biote...attack-presymptomatic-alzheimers-ends-failure

 

[anonymous]

Another knock back for amyloid: Roche's approach to presymptomatic Alzheimer's ends in failure | Fierce Biotech


https://www.fiercebiotech.com/biote...attack-presymptomatic-alzheimers-ends-failure

Maybe now companies will start investing money into different MOAs because Amyloid is not the answer

 

[anonymous]

Maybe now companies will start investing money into different MOAs because Amyloid is not the answer

Too much money already spent on anti-amyloid and tau therapies. You’ll see all sorts of data manipulations and supposed efficacy in certain population subsets before you ever see these companies pack up their bags and start over. Too many companies like Biogen that are willing to push forward with something that obviously doesn’t work - all you need are a few politicians in your pocket to clear the approval pathway for you. It’s a sad state of affairs. When they’ve spent billions already on multiple products on the pipeline, they’ll do everything the can to push forward.